These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31682300)

  • 41. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of beta-strand 5A of plasminogen activator inhibitor-1 in regulation of its latency transition and inhibitory activity by vitronectin.
    Jensen S; Kirkegaard T; Pedersen KE; Busse M; Preissner KT; Rodenburg KW; Andreasen PA
    Biochim Biophys Acta; 2002 Jun; 1597(2):301-10. PubMed ID: 12044908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides.
    Germer M; Kanse SM; Kirkegaard T; Kjøller L; Felding-Habermann B; Goodman S; Preissner KT
    Eur J Biochem; 1998 May; 253(3):669-74. PubMed ID: 9654064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule.
    Sui GC; Wiman B
    Biochem J; 1998 Apr; 331 ( Pt 2)(Pt 2):409-15. PubMed ID: 9531478
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin.
    Fa M; Karolin J; Aleshkov S; Strandberg L; Johansson LB; Ny T
    Biochemistry; 1995 Oct; 34(42):13833-40. PubMed ID: 7577977
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulation of cell adhesion by PAI-1.
    Loskutoff DJ; Curriden SA; Hu G; Deng G
    APMIS; 1999 Jan; 107(1):54-61. PubMed ID: 10190280
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Probing nanosecond motions of plasminogen activator inhibitor-1 by time-resolved fluorescence anisotropy.
    Ko CW; Wei Z; Marsh RJ; Armoogum DA; Nicolaou N; Bain AJ; Zhou A; Ying L
    Mol Biosyst; 2009 Sep; 5(9):1025-31. PubMed ID: 19668868
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The cluster of basic amino acids in vitronectin contributes to its binding of plasminogen activator inhibitor-1: evidence from thrombin-, elastase- and plasmin-cleaved vitronectins and anti-peptide antibodies.
    Gechtman Z; Belleli A; Lechpammer S; Shaltiel S
    Biochem J; 1997 Jul; 325 ( Pt 2)(Pt 2):339-49. PubMed ID: 9230112
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectin.
    Kamikubo Y; Okumura Y; Loskutoff DJ
    J Biol Chem; 2002 Jul; 277(30):27109-19. PubMed ID: 12019263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability.
    Jensen JK; Thompson LC; Bucci JC; Nissen P; Gettins PG; Peterson CB; Andreasen PA; Morth JP
    J Biol Chem; 2011 Aug; 286(34):29709-17. PubMed ID: 21697084
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Construction of a plasminogen activator inhibitor-1 variant without measurable affinity to vitronectin but otherwise normal.
    Jensen JK; Durand MK; Skeldal S; Dupont DM; Bødker JS; Wind T; Andreasen PA
    FEBS Lett; 2004 Jan; 556(1-3):175-9. PubMed ID: 14706846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Kinetically controlled folding of the serpin plasminogen activator inhibitor 1.
    Wang Z; Mottonen J; Goldsmith EJ
    Biochemistry; 1996 Dec; 35(51):16443-8. PubMed ID: 8987976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.
    Li SH; Reinke AA; Sanders KL; Emal CD; Whisstock JC; Stuckey JA; Lawrence DA
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):E4941-9. PubMed ID: 24297881
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.
    Sharp AM; Stein PE; Pannu NS; Carrell RW; Berkenpas MB; Ginsburg D; Lawrence DA; Read RJ
    Structure; 1999 Feb; 7(2):111-8. PubMed ID: 10368279
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
    Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J
    Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding.
    Wind T; Jensen MA; Andreasen PA
    Eur J Biochem; 2001 Feb; 268(4):1095-106. PubMed ID: 11179976
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
    Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
    Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin.
    Seiffert D; Loskutoff DJ
    Biochim Biophys Acta; 1991 May; 1078(1):23-30. PubMed ID: 1710930
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A model for the three-dimensional structure of human plasma vitronectin from small-angle scattering measurements.
    Lynn GW; Heller WT; Mayasundari A; Minor KH; Peterson CB
    Biochemistry; 2005 Jan; 44(2):565-74. PubMed ID: 15641781
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C.
    Dupont DM; Blouse GE; Hansen M; Mathiasen L; Kjelgaard S; Jensen JK; Christensen A; Gils A; Declerck PJ; Andreasen PA; Wind T
    J Biol Chem; 2006 Nov; 281(47):36071-81. PubMed ID: 17018527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.